Quick Facts
| Property | Value |
|---|---|
| Category | Mitochondrial-Targeted Tetrapeptide |
| Risk Level | Experimental |
| Administration | Subcutaneous Injection |
| Typical Frequency | Daily |
| Estimated Half-Life | Approximately 2–4 Hours |
| Primary Research Interest | Mitochondrial Function / Cardiac Support / Longevity |
This material is provided strictly for educational and informational purposes related to peptide research and experimental mitochondrial compounds. SS-31 is a biologically active mitochondrial-targeted peptide with limited large-scale long-term human safety data. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 50 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.5 mL
- Final Concentration: 20.00 mg/mL
At this concentration:
• 2.5 mg = 0.125 mL (12.5 units)
• 5.0 mg = 0.250 mL (25.0 units)
• 7.5 mg = 0.375 mL (37.5 units)
• 10 mg = 0.500 mL (50.0 units)
2. Route of Administration
SS-31 is most commonly administered as a subcutaneous injectable mitochondrial-targeted peptide compound.
- Primary Route: SubQ Injection
- Preferred Timing: Flexible daily administration timing
- Administration Notes: Long-term consistency is commonly emphasized because effects are often described as gradual and cumulative
3. Typical Research Protocols
- Product Strength: 20.00 mg/mL
- Typical Delivered Amount: 2.5 mg/day × 2 weeks, then 5.0 mg/day × 2 weeks, then 7.5 mg/day × 2 weeks, then 10 mg/day × 4 weeks
- Frequency: Daily
- Cycle Length: 10 weeks on / 2 weeks off
- Special Notes: The effects of SS-31 are gradual and highly individualized. Individuals with advanced cardiac conditions should only use this compound under the supervision of a qualified medical professional. SS-31 is commonly stacked with other mitochondrial enhancers including NAD+, methylene blue, MOTS-c, CoQ10, PQQ, ALCAR, and creatine.
4. Summary
SS-31 (Elamipretide) is an experimental mitochondrial-targeted tetrapeptide researched for its potential ability to improve mitochondrial efficiency and reduce oxidative stress signaling.
Research interest in SS-31 primarily centers around mitochondrial dysfunction, cardiac support, fatigue reduction, recovery enhancement, and longevity-associated applications.
5. Mechanism of Action
SS-31 is believed to selectively target mitochondrial membranes and interact with cardiolipin, a phospholipid involved in mitochondrial energy production.
- Improved mitochondrial efficiency
- Reduced oxidative stress signaling
- Enhanced cellular energy production
- Potential cardiac support
- Reduced mitochondrial membrane damage
- Improved exercise recovery signaling
The compound is often discussed as one of the more advanced mitochondrial-targeted experimental peptides currently under investigation.
6. Potential Benefits
- Potential mitochondrial support
- Improved exercise tolerance
- Reduced fatigue
- Possible cardiac support effects
- Enhanced recovery signaling
- Theoretical longevity-associated benefits
7. Potential Risks / Side Effects
Experimental
- Limited long-term human safety data
- Injection site irritation
- Fatigue or lethargy
- Dizziness
- Unknown long-term mitochondrial effects
- Potential cardiovascular signaling changes
8. Half-Life
SS-31 is commonly discussed as having an estimated plasma half-life of approximately 2–4 hours.
Despite the relatively short circulating duration, downstream mitochondrial effects may accumulate gradually over time.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Advanced cardiovascular disease without medical supervision
- Pregnancy or breastfeeding
- Severe metabolic disorders
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Mitochondrial physiology literature
- Peer-reviewed cardiology and longevity journals
CKF Tide Tables 